ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG Posted on February 20, 2019 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Agreement - FINAL
ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL Posted on December 20, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Amendment- FINAL
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on November 14, 2018 by ARCA IT - Press Release, Uncategorized ABIO - 3Q18 Financial Results and Business Update - FINAL
GENETIC-AF PHASE 2B CLINICAL TRIAL ATRIAL FIBRILLATION BURDEN (AFB) RESULTS PRESENTED AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS Posted on November 12, 2018 by ARCA IT - Press Release, Uncategorized AHA 2018 - GENETIC-AF AFB Poster Presentation - FINAL
GENETIC-AF Atrial Fibrillation Burden Results – AHA 2018 Posted on November 11, 2018 by ARCA IT - Uncategorized GAF AFB poster for AHA 11118
ARCA BIOPHARMA ANNOUNCES PHASE 2B GENETIC-AF ATRIAL FIBRILLATION BURDEN (AFB) RESULTS SELECTED FOR PRESENTATION AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS Posted on November 5, 2018 by ARCA IT - Press Release, Uncategorized AHA 2018 - GENETIC-AF AFB Poster Presentation Announcement - FINAL
ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial Posted on September 18, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Submission - FINAL
ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on August 9, 2018 by ARCA IT - Press Release, Uncategorized ABIO - 2Q18 Financial Results and Business Update - FINAL
ARCA BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA ON GENCARO DEVELOPMENT FOR ATRIAL FIBRILLATION Posted on July 31, 2018 by ARCA IT - Press Release, Uncategorized End of Phase 2 FDA meeting - FINAL
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress Posted on May 29, 2018 by ARCA IT - Press Release, Uncategorized ESC Heart Failure 2018 - GENETIC-AF Data Presentation - FINAL